Paul Holme

In 2013, Paul (along with 3 other co-founders) founded Alderley Analytical, a Regulatory Bioanalysis CRO based near Manchester, UK. Paul held the position of CEO, driving the success and growth of the business toward a successful exit/acquisition by Synexa Life Sciences in 2024. Prior to co-founding Alderley Analytical, Paul held the position of Director of Regulatory Bioanalysis at AstraZeneca.

An experienced scientist and manager, Paul is recognised as a motivational leader. Paul’s career spans over 34 years, working in both discovery and regulatory environments in Large Pharma and Contract Research Organisations (CRO’s). Across his career he has amassed an in-depth knowledge in toxicology, DMPK and regulatory bioanalysis. Maximising efficiency, productivity, building and managing high performing teams is something he thrives upon, with a particular focus on quality. Paul holds a BSc Honours degree in Pharmacology from the University of Manchester.